{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T06:43:13Z","timestamp":1780555393375,"version":"3.54.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,10,3]],"date-time":"2021-10-03T00:00:00Z","timestamp":1633219200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,3]],"date-time":"2021-10-03T00:00:00Z","timestamp":1633219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Kowa Co. Ltd.","award":["191203KOWA"],"award-info":[{"award-number":["191203KOWA"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Nonalcoholic fatty liver disease (NAFLD) and metabolic dysfunction associated fatty liver disease (MAFLD) have important associations with cardiovascular disease (CVD). The main objective of this study was to compare the frequency of incidence rate of CVD in the NAFLD or MAFLD patients utilizing a large claims database.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Using the JMDC database from April 2013 to March 2019, we retrospectively analyzed data for 1,542,688 and 2,452,949 people to estimate the relationship between CVD and NAFLD, MAFLD, respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The incidence rates of CVD were 0.97 (95% CI 0.94\u20131.01) and 2.82 (95% CI 2.64\u20133.01) per 1000 person-years in the non-NAFLD and NAFLD groups, respectively, and 1.01 (95% CI 0.98\u20131.03) and 2.69 (95% CI 2.55\u20132.83) per 1000 person-years in the non-MAFLD and MAFLD groups, respectively. The overall prevalence of hypertriglyceridemia and diabetes mellitus (DM) was 13.1, and 4.2%, respectively, in the non-NAFLD group and 63.6, and 20.2%, respectively, in the NAFLD group. The overall prevalenceof hypertriglyceridemia and DM was 13.6 and 4.3%, respectively, in the non-MAFLD group and 64.1, and 20.6%, respectively, in the MAFLD group. HRs for CVD increased with hypertriglyceridemia and DM.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Results indicated that incident rate of CVD increased with NAFLD\/MAFLD; the complication rate of DM and hypertriglyceridemia among NAFLD\/MAFLD patients is high and may affect the development of CVD.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00535-021-01828-6","type":"journal-article","created":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T21:42:13Z","timestamp":1633383733000},"page":"1022-1032","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":85,"title":["Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan"],"prefix":"10.1007","volume":"56","author":[{"given":"Masato","family":"Yoneda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuma","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kento","family":"Imajo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaomi","family":"Kessoku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asako","family":"Nogami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuma","family":"Higurashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiro","family":"Hosono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6263-1436","authenticated-orcid":false,"given":"Atsushi","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,3]]},"reference":[{"key":"1828_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73\u201384.","journal-title":"Hepatology"},{"key":"1828_CR2","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/S2468-1253(19)30039-1","volume":"4","author":"J Li","year":"2019","unstructured":"Li J, Zou B, Yeo YH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999\u20132019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2019;4:389\u201398.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1828_CR3","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S2213-8587(14)70032-4","volume":"2","author":"H Yki-J\u00e4rvinen","year":"2014","unstructured":"Yki-J\u00e4rvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol. 2014;2:901\u201310.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1828_CR4","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73:202\u20139.","journal-title":"J Hepatol"},{"key":"1828_CR5","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","volume":"149","author":"P Angulo","year":"2015","unstructured":"Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149:389-97.e10.","journal-title":"Gastroenterology"},{"key":"1828_CR6","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.jhep.2017.07.027","volume":"67","author":"H Hagstr\u00f6m","year":"2017","unstructured":"Hagstr\u00f6m H, Nasr P, Ekstedt M, et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol. 2017;67:1265\u201373.","journal-title":"J Hepatol"},{"key":"1828_CR7","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00535-018-1516-5","volume":"54","author":"HE Park","year":"2019","unstructured":"Park HE, Lee H, Choi SY, et al. Clinical significance of hepatic steatosis according to coronary plaque morphology: assessment using controlled attenuation parameter. J Gastroenterol. 2019;54:271\u201380.","journal-title":"J Gastroenterol"},{"key":"1828_CR8","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.jhep.2017.11.023","volume":"68","author":"YH Lee","year":"2018","unstructured":"Lee YH, Kim KJ, Yoo ME, et al. Association of non-alcoholic steatohepatitis with subclinical myocardial dysfunction in non-cirrhotic patients. J Hepatol. 2018;68:764\u201372.","journal-title":"J Hepatol"},{"key":"1828_CR9","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1056\/NEJMra0912063","volume":"363","author":"G Targher","year":"2010","unstructured":"Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010;363:1341\u201350.","journal-title":"N Engl J Med"},{"key":"1828_CR10","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1093\/eurheartj\/ehr453","volume":"33","author":"LS Bhatia","year":"2012","unstructured":"Bhatia LS, Curzen NP, Calder PC, et al. Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor? Eur Heart J. 2012;33:1190\u2013200.","journal-title":"Eur Heart J"},{"issue":"20","key":"1828_CR11","first-page":"31717","volume":"S1542\u20133565","author":"H Lee","year":"2020","unstructured":"Lee H, Lee YH, Kim SU, Kim HC. Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: a Nationwide Cohort Study. Clin Gastroenterol Hepatol. 2020;S1542\u20133565(20):31717\u201321.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1828_CR12","doi-asserted-by":"crossref","unstructured":"Tsutsumi T, Eslam M, Kawaguchi T, et al. MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: generalized estimating equation approach. Hepatol Res. 2021 (Online ahead of print)","DOI":"10.1111\/hepr.13685"},{"key":"1828_CR13","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jhep.2017.09.021","volume":"68","author":"A Lonardo","year":"2018","unstructured":"Lonardo A, Nascimbeni F, Mantovani A. Hypertension, diabetes, atherosclerosis and NASH: cause or consequence? J Hepatol. 2018;68:335\u201352.","journal-title":"J Hepatol"},{"key":"1828_CR14","doi-asserted-by":"publisher","first-page":"l5367","DOI":"10.1136\/bmj.l5367","volume":"367","author":"M Alexander","year":"2019","unstructured":"Alexander M, Loomis AK, van der Lei J, et al. Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults. BMJ. 2019;367:l5367.","journal-title":"BMJ."},{"key":"1828_CR15","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1161\/CIRCULATIONAHA.108.837054","volume":"118","author":"S Sasayama","year":"2008","unstructured":"Sasayama S. Heart disease in Asia. Circulation. 2008;118:2669\u201371.","journal-title":"Circulation"},{"key":"1828_CR16","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1161\/01.CIR.89.1.109","volume":"89","author":"S Baba","year":"1994","unstructured":"Baba S, Ozawa H, Sakai Y, et al. Heart disease death in Japanese urban area evaluated by clinical and police records. Circulation. 1994;89:109\u201315.","journal-title":"Circulation"},{"key":"1828_CR17","doi-asserted-by":"publisher","first-page":"413","DOI":"10.2188\/jea.JE20090066","volume":"20","author":"S Kimura","year":"2010","unstructured":"Kimura S, Sato T, Ikeda S, et al. Development of a database of health insurance claims: standardization of disease classifications and anonymous record linkage. J Epidemiol. 2010;20:413\u20139.","journal-title":"J Epidemiol"},{"key":"1828_CR18","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-230X-6-33","volume":"6","author":"G Bedogni","year":"2006","unstructured":"Bedogni G, Bellentani S, Miglioli L, et al. The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33.","journal-title":"BMC Gastroenterol"},{"key":"1828_CR19","first-page":"1388","volume":"64","author":"European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity","year":"2016","unstructured":"European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity. EASL-EASD-EASO Clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388\u2013402.","journal-title":"J Hepatol"},{"key":"1828_CR20","doi-asserted-by":"crossref","unstructured":"Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018;67:328\u20135715.4 Wong VW JGH 2018;33:70\u201385.","DOI":"10.1002\/hep.29367"},{"key":"1828_CR21","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/jgh.13857","volume":"33","author":"VW Wong","year":"2018","unstructured":"Wong VW, Chan WK, Chitturi S, et al. Asia-Pacific working party on non-alcoholic fatty liver disease guidelines 2017-part 1: definition, risk factors and assessment. J Gastroenterol Hepatol. 2018;33:70\u201385.","journal-title":"J Gastroenterol Hepatol"},{"issue":"Suppl 1","key":"1828_CR22","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.2337\/dc13-S011","volume":"36","author":"American Diabetes Association","year":"2013","unstructured":"American Diabetes Association. Standards of medical care in diabetes\u20142013. Diabetes Care. 2013;36(Suppl 1):S11-66.","journal-title":"Diabetes Care"},{"key":"1828_CR23","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/s00535-015-1050-7","volume":"50","author":"S Watanabe","year":"2015","unstructured":"Watanabe S, Hashimoto E, Ikejima K, et al. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis. J Gastroenterol. 2015;50:364\u201377.","journal-title":"J Gastroenterol"},{"key":"1828_CR24","first-page":"1887","volume":"45","author":"J Textor","year":"2016","unstructured":"Textor J, van der Zander B, Gilthorpe MS, et al. Robust causal inference using directed acyclic graphs: the R package \u201cdagitty.\u201d Int J Epidemiol. 2016;45:1887\u201394.","journal-title":"Int J Epidemiol"},{"key":"1828_CR25","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.1161\/CIRCULATIONAHA.107.750117","volume":"118","author":"H Iso","year":"2008","unstructured":"Iso H. Changes in coronary heart disease risk among Japanese. Circulation. 2008;118:2725\u20139.","journal-title":"Circulation"},{"key":"1828_CR26","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1093\/aje\/kwn064","volume":"167","author":"N Rumana","year":"2008","unstructured":"Rumana N, Kita Y, Turin TC, et al. Trend of increase in the incidence of acute myocardial infarction in a Japanese population: Takashima AMI Registry, 1990\u20132001. Am J Epidemiol. 2008;167:1358\u201364.","journal-title":"Am J Epidemiol"},{"key":"1828_CR27","doi-asserted-by":"publisher","first-page":"784","DOI":"10.5551\/jat.19356","volume":"21","author":"K Nishimura","year":"2014","unstructured":"Nishimura K, Okamura T, Watanabe M, et al. Predicting coronary heart disease using risk factor categories for a Japanese urban population, and comparison with the framingham risk score: the suita study. J Atheroscler Thromb. 2014;21:784\u201398.","journal-title":"J Atheroscler Thromb"},{"key":"1828_CR28","doi-asserted-by":"crossref","unstructured":"Guerreiro GTS, Longo L, Fonseca MA, et al. Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD? Hepatol Int. 2021 [Online ahead of print].","DOI":"10.1007\/s12072-021-10157-y"},{"key":"1828_CR29","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1007\/s12072-021-10157-y","volume":"15","author":"GTS Guerreiro","year":"2021","unstructured":"Guerreiro GTS, Longo L, Fonseca MA, et al. Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD? Hepatol Int. 2021;15:380\u201391.","journal-title":"Hepatol Int"},{"key":"1828_CR30","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/hep.23094","volume":"50","author":"K Fujita","year":"2009","unstructured":"Fujita K, Nozaki Y, Wada K, et al. Dysfunctional very-low-density lipoprotein synthesis and release is a key factor in nonalcoholic steatohepatitis pathogenesis. Hepatology. 2009;50:772\u201380.","journal-title":"Hepatology"},{"key":"1828_CR31","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1046\/j.1440-1746.2002.02846.x","volume":"17","author":"K Omagari","year":"2002","unstructured":"Omagari K, Kadokawa Y, Masuda J, et al. Fatty liver in non-alcoholic non-overweight Japanese adults: incidence and clinical characteristics. J Gastroenterol Hepatol. 2002;17:1098\u2013105.","journal-title":"J Gastroenterol Hepatol"},{"key":"1828_CR32","doi-asserted-by":"publisher","first-page":"722","DOI":"10.7326\/0003-4819-143-10-200511150-00009","volume":"143","author":"M Hamaguchi","year":"2005","unstructured":"Hamaguchi M, Kojima T, Takeda N, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med. 2005;143:722\u20138.","journal-title":"Ann Intern Med"},{"key":"1828_CR33","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1007\/s00535-012-0533-z","volume":"47","author":"Y Eguchi","year":"2012","unstructured":"Eguchi Y, Hyogo H, Ono M, et al. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol. 2012;47:586\u201395.","journal-title":"J Gastroenterol."},{"key":"1828_CR34","doi-asserted-by":"crossref","unstructured":"Yamada MH, Fujihara K, Kodama S, et al. Associations of systolic blood pressure and diastolic blood pressure with the incidence of coronary artery disease or cerebrovascular disease according to glucose status. Diabetes Care. 2021 [Online ahead of print].","DOI":"10.2337\/figshare.14368454"},{"key":"1828_CR35","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1111\/apt.13063","volume":"41","author":"E Vanni","year":"2015","unstructured":"Vanni E, Bugianesi E. Editorial: utility and pitfalls of Fatty Liver Index in epidemiologic studies for the diagnosis of NAFLD. Aliment Pharmacol Ther. 2015;41:406\u20137.","journal-title":"Aliment Pharmacol Ther"},{"key":"1828_CR36","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/ajg.2016.517","volume":"112","author":"PY Kwo","year":"2017","unstructured":"Kwo PY, Cohen SM, Lim JK. ACG Clinical Guideline: evaluation of abnormal liver chemistries. Am J Gastroenterol. 2017;112:18\u201335.","journal-title":"Am J Gastroenterol"},{"key":"1828_CR37","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.jhep.2016.05.013","volume":"65","author":"G Targher","year":"2016","unstructured":"Targher G, Byrne CD, Lonardo A, et al. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol. 2016;65:589\u2013600.","journal-title":"J Hepatol"},{"key":"1828_CR38","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1002\/hep.29085","volume":"65","author":"PS Dulai","year":"2017","unstructured":"Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology. 2017;65:1557\u201365.","journal-title":"Hepatology"},{"issue":"4","key":"1828_CR39","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","volume":"69","author":"C Estes","year":"2018","unstructured":"Estes C, Anstee QM, Arias-Loste MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016\u20132030. J Hepatol. 2018;69(4):896\u2013904.","journal-title":"J Hepatol"},{"key":"1828_CR40","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.metabol.2015.09.017","volume":"65","author":"A Lonardo","year":"2016","unstructured":"Lonardo A, Sookoian S, Pirola CJ, Targher G. Non-alcoholic fatty liver disease and risk of cardiovascular disease. Metab Clin Exp. 2016;65:1136\u201350.","journal-title":"Metab Clin Exp"},{"key":"1828_CR41","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.atherosclerosis.2015.02.011","volume":"239","author":"M Rifai","year":"2015","unstructured":"Rifai M, Silverman MG, Nasir K, et al. The association of nonalcoholic fatty liver disease, obesity, and metabolic syndrome, with systemic inflammation and subclinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis. 2015;239:629\u201333.","journal-title":"Atherosclerosis"},{"key":"1828_CR42","doi-asserted-by":"publisher","first-page":"13306","DOI":"10.3748\/wjg.v20.i37.13306","volume":"20","author":"S Fargion","year":"2014","unstructured":"Fargion S, Porzio M, Fracanzani AL. Nonalcoholic fatty liver disease and vascular disease: state-of-the-art. World J Gastroenterol. 2014;20:13306\u201324.","journal-title":"World J Gastroenterol"},{"key":"1828_CR43","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/nrendo.2015.58","volume":"11","author":"G Iacobellis","year":"2015","unstructured":"Iacobellis G. Local and systemic effects of the multifaceted epicardial adipose tissue depot. Nat Rev Endocrinol. 2015;11:363\u201371.","journal-title":"Nat Rev Endocrinol"},{"key":"1828_CR44","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1002\/hep4.1105","volume":"1","author":"T Tada","year":"2017","unstructured":"Tada T, Kumada T, Toyoda H, et al. Progression of liver fibrosis is associated with non-liver-related mortality in patients with nonalcoholic fatty liver disease. Hepatol Commun. 2017;1:899\u2013910.","journal-title":"Hepatol Commun"},{"key":"1828_CR45","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12876-018-0900-1","volume":"18","author":"N Akuta","year":"2018","unstructured":"Akuta N, Kawamura Y, Arase Y, et al. Hepatocellular carcinoma is the most common liver-related complication in patients with histopathologically-confirmed NAFLD in Japan. BMC Gastroenterol. 2018;18:165.","journal-title":"BMC Gastroenterol"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-021-01828-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-021-01828-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-021-01828-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T18:09:45Z","timestamp":1634839785000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-021-01828-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,3]]},"references-count":45,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["1828"],"URL":"https:\/\/doi.org\/10.1007\/s00535-021-01828-6","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,3]]},"assertion":[{"value":"7 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}